CompletedNCT00402324
Official study titleA Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode
This study has finished and is no longer accepting participants.
In HialeahBipolarityMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Eli Lilly and Company
CompletedNCT01822730
Official study titleA Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
This study has finished and is no longer accepting participants.
In ChangshaSchizophreniaMedication studyAges 19–65
- Countries
- China
- Sponsor
- Wei Hao
CompletedNCT02555150
Official study titleA Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
This study has finished and is no longer accepting participants.
In CharlottesvilleADHDMedication studyAges 18–35
- Countries
- United States
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Active Not RecruitingNCT04961190
Official study titleA Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom
This study is no longer accepting new participants.
Multiple locations, including BirminghamPTSDMedication studyAges 18–75
- Countries
- United States
- Sponsor
- University of Pennsylvania
TerminatedNCT01813643
Official study titleA Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment
This study ended early.
In ChangshaSchizophreniaMedication studyAges 19–65
- Countries
- China
- Sponsor
- Wei Hao
CompletedNCT00253110
Official study titleA Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen, LP
CompletedACTRN12620001298909
Official study titleA randomised controlled trial evaluating two universal anxiety and depression prevention programs for children: Building resilience to manage worry
This study has finished and is no longer accepting participants.
In AustraliaAnxiety, DepressionInterventional studyAges 8–13
- Countries
- Australia
- Sponsor
- Dr Kristy Johnstone
CompletedNCT00034905
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- AstraZeneca
CompletedNCT00044044
What is this study about?Researchers compared Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg and placebo, tracking side effects to assess safety in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Sumitomo Pharma America, Inc.
CompletedNCT00314340
Official study titleA CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
This study has finished and is no longer accepting participants.
Location not clearly listedAddictionMedication studyAges 18–70
- Countries
- Sponsor
- University of California, Davis
CompletedNCT00249223
Official study titleRisperidone Depot (Microspheres) vs. Risperidone Tablets - a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT00843687
Official study titleComparative Single-Dose Pharmacokinetics and Safety of Gluteal and Deltoid Intramuscular Injection of Long-Acting Injectable Risperidone in Subjects With Chronic Stable Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.